ZNTL - Wedbush cuts Zentalis to neutral cites strategy shift for ovarian cancer drug
2023-11-08 11:58:55 ET
More on Zentalis Pharmaceuticals
- Zentalis: A Buy As Small Molecule Trials Continue To Advance
- Zentalis hits 52-week low as Leerink downgrades on data for lead asset
- Seeking Alpha’s Quant Rating on Zentalis Pharmaceuticals
- Historical earnings data for Zentalis Pharmaceuticals
- Financial information for Zentalis Pharmaceuticals
For further details see:
Wedbush cuts Zentalis to neutral, cites strategy shift for ovarian cancer drug